Join
Live feed
·
PRReleasevia Quantisnow
KALA BIO Inc. logo

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

ByQuantisnow·Wall Street's wire, on your screen.
KALA· KALA BIO Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KALA (KALA BIO Inc.) and more on Quantisnow.